Bo Li

Dr. Bo Li

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
CHChu Han
Chu Han
YLYuanyuan Liu
Yuanyuan Liu
RDRongji Dai
Rongji Dai
NINafissa Ismail
Nafissa Ismail
WSWeijun Su
Weijun Su
BLBo Li
Bo Li
Ferroptosis is a novel regulated cell death pattern discovered when studying the mechanism of erastin-killing RAS mutant tumor cells in 2012. It is an iron-dependent programmed cell death pathway mainly caused by an increased redox imbalance but with distinct biological and morphology characteristics when compared to other known cell death patterns. Ferroptosis is associated with various diseases including acute kidney injury, cancer, and cardiovascular, neurodegenerative, and hepatic diseases. Moreover, activation or inhibition of ferroptosis using a variety of ferroptosis initiators and inhibitors can modulate disease progression in animal models. In this review, we provide a comprehensive analysis of the characteristics of ferroptosis, its initiators and inhibitors, and the potential role of its main metabolic pathways in the treatment and prevention of various diseased states. We end the review with the current knowledge gaps in this area to provide direction for future research on ferroptosis.

1 March 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LCLin Cong
Lin Cong
XDXiyu Dong
Xiyu Dong
YWYan Wang
Yan Wang
YDYulin Deng
Yulin Deng
BLBo Li
Bo Li
RDRongji Dai
Rongji Dai

1 April 2020 in Marine Pollution Bulletin
Verified
Journal Article
Closed access
DFDongdong Fu
Dongdong Fu
CCChein Min Chen
Chein Min Chen
HQHuaiyuan Qi
Huaiyuan Qi
ZFZhengquan Fan
Zhengquan Fan
ZWZezheng Wang
Zezheng Wang
BLBo Li
Bo Li

22 November 2021 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
HWHaiyang Wang
Haiyang Wang
WWWenbo Wang
Wenbo Wang
LLLu Liu
Lu Liu
MWMeng Wang
Meng Wang
GLGuowei Li
Guowei Li
WXWei Xue
Wei Xue

Verified
Journal Article
Open access
PDF file
YCYanlu Cao
Yanlu Cao
BLBo Li
Bo Li
NINafissa Ismail
Nafissa Ismail
KSKevin B Smith
Kevin B Smith
TLTianmei Li
Tianmei Li
YDYulin Deng
Yulin Deng
Endogenous and exogenous neurotoxins are important factors leading to neurodegenerative diseases. In the 1980s, the discovery that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) contributes to Parkinson’s disease (PD) symptoms led to new research investigations on neurotoxins. An abnormal metabolism of endogenous substances, such as condensation of bioamines with endogenous aldehydes, dopamine (DA) oxidation, and kynurenine pathway, can produce endogenous neurotoxins. Neurotoxins may damage the nervous system by inhibiting mitochondrial activity, increasing oxidative stress, increasing neuroinflammation, and up-regulating proteins related to cell death. This paper reviews the biological synthesis of various known endogenous neurotoxins and their toxic mechanisms.

7 March 2023 in Acta Biomaterialia
Verified
Journal Article
Open access
BLBo LI
Bo LI
TYTong Yang
Tong Yang
JLJin Liu
Jin Liu
XYXixi Yu
Xixi Yu
XLXinying Li
Xinying Li
LCLiang Chen
Liang Chen
Non-small cell lung cancer (NSCLC) remains the most frequently diagnosed lung cancer and the leading cause of cancer-related mortality worldwide. PD-1/PD-L1 axis inhibitors have changed the treatment paradigm for various cancer types, including NSCLC. However, success of these inhibitors in lung cancer clinic is severely limited by their inability to inhibit the PD-1/PD-L1 signaling axis due to heavy glycosylation and heterogeneity expression of PD-L1 in NSCLC tumor tissue. Taking advantage of the facts that tumor cell derived nanovesicles could efficiently accumulate in the homotypic tumor sites due to their innate targeting abilities and that specific and high affinity existed between PD-1 and PD-L1, we developed NSCLC targeting biomimetic nanovesicles (NV) cargos from genetically engineered NSCLC cell lines that overexpressed PD-1 (P-NV). We showed that P-NVs efficiently bound NSCLC cells in vitro and targeted tumor nodules in vivo. We further loaded P-NVs with 2-deoxy-D-glucose (2-DG) and doxorubicin (DOX), and found that these drugs co-loaded P-NVs efficiently shrank lung cancers in mouse models for both allograft and autochthonous tumor. Mechanistically, drug-loaded P-NVs efficiently caused cytotoxicity to tumor cells and simultaneously activated anti-tumor immunity function of tumor-infiltrating T cells. Our data therefore strongly argue that 2-DG and DOX co-loaded, PD-1-displaying nanovesicles is a highly promising therapy for treatment of NSCLC in clinic. STATEMENT OF SIGNIFICANCE: Lung cancer cells overexpressing PD-1 are developed for preparing nanoparticles (P-NV). PD-1s displayed on NVs enhance their homologous targeting abilities to tumor cells expressing PD-L1s. Chemotherapeutics such as DOX and 2-DG, are packaged in such nanovesicles (PDG-NV). These nanovesicles efficiently delivered chemotherapeutics to tumor nodules specifically. The synergy between DOX and 2-DG is observed in inhibiting lung cancer cells in vitro and in vivo. Importantly, 2-DG causes deglycosylation and downregulation of PD-L1 on tumor cells while PD-1 displayed on nanovesicles' membrane blocks PD-L1 on tumor cells. 2-DG loaded nanoparticles thus activate anti-tumor activities of T cells in the tumor microenvironment. Our work thus highlights the promising antitumor activity of PDG-NVs, which warrants further clinical evaluation.